|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | Centre Henri Becquerel |
|---|---|
| Information provided by: | Centre Henri Becquerel |
| ClinicalTrials.gov Identifier: | NCT00934505 |
Purpose
The poor prognosis in the early-stage of oeasophagus carcinoma cancer is due to potential worsening of the disease (local relapse, metastasis), to insufficient efficacy and toxicity of actual treatments.
FDG-PET is a medical imaging modality allowing the quantification of the tumour glucose consumption. Then, this exam is used for pathology staging, target volume definition for RT, and treatment efficiency few months after CRT. Our assumption is that an FDG-PET exam during the course of CRT might be predictive of the treatment efficiency few months later.
In this study, we propose to perform 4 FDG-PET: first "PET1" before chemo-radiotherapy, second "PET2" during the chemo-radiotherapy (see RTEP1), third and fourth "PET3" "PET4" 3month and 12 month after the end of radiotherapy.
We will investigate the performances of FDG-PET performed during CRT for the prediction of the one-year patient heath outcome. If the predictive value of TEP2 is confirmed, we would be able to optimize the planning treatment during the course of the therapy.
| Condition |
|---|
|
Oesaphagus Carcinoma Cancer |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Predictive Value of FDG-TEP During Exclusive Chemo-Radiotherapy (CRT) in Patients With Oesophagus Carcinoma Cancer on the One-Year Survival (RTEP3) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Diagnosed patients a carcinoma of the oesophagus histologiquement proved
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: THILLAYS Marc, RCA | 00330232082497 | marc.thillays@rouen.fnclcc.fr |
| France | |
| CLCC H.Becquerel | Recruiting |
| Rouen, Haute Normandie, France, 76000 | |
| Contact: THILLAYS Marc, RT 0033232082497 marc.thillays@touen.fnclcc.fr | |
| Contact: GOUEL Pierrick, RT 0033232082497 pierrick.gouel@rouen.fnclcc.fr | |
| Sub-Investigator: BENYOUCEF Ahmed, MD | |
| Principal Investigator: | VERA Pierre, MD phD | CHBecquerel |
| Principal Investigator: | MICHEL Pierre, MD phD | CHRU Rouen |
More Information
| Responsible Party: | PU PH VERA Pierre, CHBecquerel |
| ClinicalTrials.gov Identifier: | NCT00934505 History of Changes |
| Other Study ID Numbers: | CHB08-02 |
| Study First Received: | July 7, 2009 |
| Last Updated: | December 15, 2010 |
| Health Authority: | France: Institutional Ethical Committee |
|
Positron-Emission Tomography PET Scan FDG |
Oesophagus Carcinoma cancer chemo-Radiation Oncology SUV |
|
Carcinoma Esophageal Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Gastrointestinal Neoplasms |
Digestive System Neoplasms Neoplasms by Site Head and Neck Neoplasms Digestive System Diseases Esophageal Diseases Gastrointestinal Diseases |
